| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(9 years from now) | |
| US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
Sotyktu is owned by Bristol.
Sotyktu contains Deucravacitinib.
Sotyktu has a total of 3 drug patents out of which 0 drug patents have expired.
Sotyktu was authorised for market use on 09 September, 2022.
Sotyktu is available in tablet;oral dosage forms.
Sotyktu can be used as treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Drug patent challenges can be filed against Sotyktu from 09 September, 2026.
The generics of Sotyktu are possible to be released after 07 November, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Dosage: TABLET;ORAL
SOTYKTU family patents
